IN THE CLAIMS

1. (Original) A pharmaceutical composition comprising a compound of the structure



(I)

(I)

wherein Y, at each occurrence, is independently selected from the group consisting of C(O), N, CR^1, $C(R^2)(R^3)$, NR^5, CH, O and S;

q is an integer of from 3 to 10;

A is selected from the group consisting of O, S, $C(R^{16})(R^{17})$ and NR^6;

E is selected from the group consisting of CH_2, O, S, and NR^7;

J is selected from the group consisting of O, S and NR^8;

T is selected from the group consisting of C(O) and $(CH_2)_b$ wherein b is an integer of from 0 to 3;

M is selected from the group consisting of $C(R^9)(R^{10})$ and $(CH_2)_u$, wherein u is an integer of from 0 to 3;

L is selected from the group consisting of O, NR^{11}, S, and $(CH_2)_n$ wherein n is an integer of 0 or 1;

X is selected from the group consisting of CO_2B, PO_3H_2, SO_3H, SO_2NH_2, SO_2NHCOR^{12}, OPO_3H_2, $C(O)NHC(O)R^{13}$, $C(O)NHSO_2R^{14}$, hydroxyl, tetrazolyl and hydrogen;

W is selected from the group consisting of C, CR^{15} and N;

B is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, hydroxyalkyl, haloalkyl, $-CF_3$, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkylalkyl, aryl, heterocyclyl, alkylaryl, aralkenyl, aralkyl, alkylheterocyclyl, heterocyclylalkyl and aryloxyalkyl; and

R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16} and R^{17} at each occurrence are independently selected from the group consisting of hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, alkenoxy, alkynoxy, thioalkoxy, hydroxyalkyl, aliphatic acyl, $-CF_3$, $-CO_2H$, -SH, -CN, $-NO_2$, $-NH_2$, -OH, alkynylamino, alkoxycarbonyl, heterocycloyl, carboxy, $-N(C_1-C_3$ alkyl)$-C(O)(C_1-C_3$ alkyl), $-NHC(O)N(C_1-C_3$ alkyl)$C(O)NH(C_1-C_3$alkyl), $-NHC(O)NH(C_1-C_6$ alkyl), $-NHSO_2(C_1-C_3$ alkyl), $-NHSO_2$(aryl), alkoxyalkyl, alkylamino, alkenylamino, di(C_1-C_3)amino, $-C(O)O-(C_1-C_3)$alkyl, $-C(O)NH-(C_1-C_3)$alkyl, $-C(O)N(C_1-C_3$ alkyl)$_2$, -CH=NOH, $-PO_3H_2$, $-OPO_3H_2$, haloalkyl, alkoxyalkoxy, carboxaldehyde, carboxamide, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkylalkyl, aryl, aroyl, aryloxy, arylamino, biaryl, thioaryl, diarylamino, heterocyclyl, alkylaryl, aralkenyl, aralkyl, alkylheterocyclyl, heterocyclylalkyl, sulfonyl, $-SO_2-(C_1-C_3$ alkyl), $-SO_3-(C_1-C_3$ alkyl), sulfonamido, carbamate, aryloxyalkyl and –C(O)NH(benzyl) groups;

wherein B, R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16} and R^{17} are unsubstituted or substituted with at least one electron donating or electron withdrawing group;

wherein when L is NR^{11}, R^4 and R^{11} taken together may form a ring;

and wherein when M is $C(R^9)(R^{10})$, R^9 and R^{10} taken together may form a ring;

and wherein when A is NR^6 and at least one Y is CR^1, R^1 and R^6 taken together may form a ring;

or a pharmaceutically acceptable salt thereof;

one or more other therapeutically active compounds and a pharmacologically acceptable diluent.

2. (Original) A composition of claim 1 wherein

A is NR^6;

E is NR^7;

J is O;

M is $C(R^9)(R^{10})$;

q is 4 or 5;

T is $(CH_2)_b$ wherein b is 0;

L is $(CH_2)_n$ wherein n is 0;

X is CO_2B;

W is C or CR^{15};

R^4 is selected from the group consisting of aryl, alkylaryl, aralkyl, heterocyclyl, alkylheterocyclyl and heterocyclylalkyl; and

R^6, R^7, R^9, R^{10} and R^{15} are independently selected from the group consisting of hydrogen and lower alkyl.

3. (Original) A pharmaceutical composition comprising a compound of the structure



wherein Y, at each occurrence, is independently selected from the group consisting of C(O), N, CR^1, $C(R^2)(R^3)$, NR^5, CH, O and S;

q is an integer of from 3 to 7;

T is selected from the group consisting of C(O) and $(CH_2)_b$ wherein b is an integer of 0 to 3;

L is selected from the group consisting of O, NR^{11}, S, and $(CH_2)_n$ wherein n is an integer of 0 or 1;

W is selected from the group consisting of C, CR^{15} and N;

B is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, hydroxyalkyl, haloalkyl, $-CF_3$, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkylalkyl, aryl, heterocyclyl, alkylaryl, aralkenyl, aralkyl, alkylheterocyclyl, heterocyclylalkyl and aryloxyalkyl; and

R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^9, R^{10}, R^{11} and R^{15} are independently selected from the group consisting of hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, alkenoxy, alkynoxy, thioalkoxy, hydroxyalkyl, aliphatic acyl, $-CF_3$, $-CO_2H$, -SH, -CN, $-NO_2$, $-NH_2$, -OH, alkynylamino, alkoxycarbonyl, heterocycloyl, carboxy, $-N(C_1-C_3$ alkyl)$-C(O)(C_1-C_3$ alkyl), $-NHC(O)N(C_1-C_3$ alkyl)$C(O)NH(C_1-C_3$alkyl), $-NHC(O)NH(C_1-C_6$ alkyl), $-NHSO_2(C_1-C_3$ alkyl), $-NHSO_2$(aryl), alkoxyalkyl, alkylamino, alkenylamino, di(C_1-C_3)amino, $-C(O)O-(C_1-C_3)$alkyl, $-C(O)NH-(C_1-C_3)$alkyl, $-C(O)N(C_1-C_3$ alkyl$)_2$, -CH=NOH, $-PO_3H_2$, $-OPO_3H_2$, haloalkyl, alkoxyalkoxy, carboxaldehyde, carboxamide, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkylalkyl, aryl, aroyl, aryloxy, arylamino, biaryl, thioaryl, diarylamino, heterocyclyl, alkylaryl, aralkenyl, aralkyl, alkylheterocyclyl, heterocyclylalkyl, sulfonyl, $-SO_2-(C_1-C_3$ alkyl), $-SO_3-(C_1-C_3$ alkyl), sulfonamido, carbamate, aryloxyalkyl and

–C(O)NH(benzyl) groups;

wherein B, R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^9, R^{10}, R^{11} and R^{15} are unsubstituted or substituted with at least one electron donating or electron withdrawing group;

wherein when L is NR^{11}, R^4 and R^{11} taken together may form a ring;

and wherein R^9 and R^{10} taken together may form a ring;

and wherein when at least one Y is CR^1, R^1 and R^6 taken together may form a ring;

or a pharmaceutically acceptable salt thereof;

one or more other therapeutically active compounds and a pharmacologically acceptable diluent.

4. (Original) A composition of claim 3 wherein

q is 4 or 5;

W is C or CR^{15};

T is $(CH_2)_b$ wherein b is 0;

L is $(CH_2)_n$ wherein n is 0;

R^4 is selected from the group consisting of aryl, alkylaryl, aralkyl, heterocyclyl, alkylheterocyclyl and heterocyclylalkyl; and

R^6, R^7, R^9, R^{10} and R^{15} are independently selected from the group consisting of hydrogen and lower alkyl.

5. (Original) A pharmaceutical composition comprising a compound of the structure



wherein Y, at each occurrence, is independently selected from the group consisting of C(O), N, CR^1, $C(R^2)(R^3)$, NR^5, CH, O and S;

q is an integer of from 2 to 5;

T is selected from the group consisting of C(O) and $(CH_2)_b$ wherein b is an integer of 0 to 3;

L is selected from the group consisting of O, NR^{11}, S, and

$(CH_2)_n$ wherein n is an integer of 0 or 1;

R^5, R^6, R^7, R^{11} and R^{18} are each independently selected from the group consisting of alkyl, alkenyl, alkynyl, hydroxyalkyl, aliphatic acyl, alkynylamino, alkoxycarbonyl, heterocycloyl, -CH=NOH, haloalkyl, alkoxyalkoxy, carboxaldehyde, carboxamide, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkylalkyl, aryl, aroyl, aryloxy, arylamino, biaryl, thioaryl, diarylamino, heterocyclyl, alkylaryl, aralkenyl, aralkyl, alkylheterocyclyl, heterocyclylalkyl, carbamate, aryloxyalkyl, hydrogen and –C(O)NH(benzyl) groups;

B is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, hydroxyalkyl, haloalkyl, $-CF_3$, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkylalkyl, aryl, heterocyclyl, alkylaryl, aralkenyl, aralkyl, alkylheterocyclyl, heterocyclylalkyl and aryloxyalkyl; and

R^1, R^2, R^3, R^4, R^9 and R^{10} are independently selected from the group consisting of hydrogen, halogen, halkyl, alkenyl, alkynyl, alkoxy, alkenoxy, alkynoxy, thioalkoxy, hydroxyalkyl, aliphatic acyl, $-CF_3$, $-CO_2H$, -SH, -CN, $-NO_2$, $-NH_2$, -OH, alkynylamino, alkoxycarbonyl, heterocycloyl, carboxy, $-N(C_1$-C_3 alkyl)-$C(O)(C_1$-C_3 alkyl), $-NHC(O)N(C_1$-C_3 alkyl)$C(O)NH(C_1$-C_3alkyl), $-NHC(O)NH(C_1$-C_6 alkyl), $-NHSO_2(C_1$-C_3 alkyl), $-NHSO_2$(aryl), alkoxyalkyl,alkylamino, alkenylamino, di(C_1-C_3)amino, $-C(O)O-(C_1$-C_3)alkyl, $-C(O)NH-(C_1$-C_3)alkyl, $-C(O)N(C_1$-C_3 alkyl)$_2$, -CH=NOH, $-PO_3H_2$, $-OPO_3H_2$, haloalkyl, alkoxyalkoxy, carboxaldehyde, carboxamide, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkylalkyl, aryl, aroyl, aryloxy, arylamino, biaryl, thioaryl, diarylamino, heterocyclyl, alkylaryl, aralkenyl, aralkyl, alkylheterocyclyl, heterocyclylalkyl, sulfonyl, $-SO_2-(C_1$-C_3 alkyl), $-SO_3-(C_1$-C_3 alkyl), sulfonamido, carbamate, aryloxyalkyl and

–C(O)NH(benzyl) groups;

wherein B, R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^9, R^{10}, R^{11} and R^{18} are unsubstituted or substituted with at least one electron donating or electron withdrawing group;

wherein when L is NR^{11}, R^4 and R^{11} taken together may form a ring;

and wherein R^9 and R^{10} taken together may form a ring;

and wherein when at least one Y is CR^1, R^1 and R^6 taken together may form a ring;

or a pharmaceutically acceptable salt thereof, one or more other therapeutically active compounds and a pharmacalogically acceptable diluent.

6. (Original) A composition of claim 5 wherein R^{18} is selected from the group consisting of

hydrogen, alkyl, aryl, aralkyl, cycloalkyl, alkylheterocyclyl, heterocyclylalkyl and heterocyclyl;

T is $(CH_2)_b$ wherein b is 0;

L is $(CH_2)_n$ wherein n is 0;

Y is selected from the group consisting of CR^1 and $C(R^2)(R^3)$ and

q is 2 or 3.

7. (Original) A composition of claim 5 wherein



is selected from the group consisting of



,



and



;

wherein R^{19}, R^{20} , R^{21} and R^{28} at each occurrence are independently selected from the group consisting of halogen, alkyl, alkenyl, alkynyl, alkoxy, alkenoxy, alkynoxy, thioalkoxy, hydroxyalkyl, aliphatic acyl, $-CF_3$, -OH, $-CO_2H$, -SH, -CN, $-NO_2$, $-NH_2$, alkynylamino, alkoxycarbonyl, heterocycloyl, carboxy, $-N(C_1-C_3$ alkyl)$-C(O)(C_1-C_3$ alkyl), $-NHC(O)N(C_1-C_3$ alkyl$)C(O)NH(C_1-C_3$alkyl), $-NHC(O)NH(C_1-C_6$ alkyl), $-NHSO_2(C_1-C_3$ alkyl), $-NHSO_2$(aryl), alkoxyalkyl, alkylamino, alkenylamino, di(C_1-C_3)amino, $-C(O)O-(C_1-C_3)$alkyl, $-C(O)NH-(C_1-C_3)$alkyl, $-C(O)N(C_1-C_3$ alkyl$)_2$, -CH=NOH, $-PO_3H_2$, $-OPO_3H_2$, haloalkyl, alkoxyalkoxy, carboxaldehyde, carboxamide, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkylalkyl, aryl, aroyl, aryloxy, arylamino, biaryl, thioaryl, diarylamino, heterocyclyl, alkylaryl, aralkenyl, aralkyl, alkylheterocyclyl, heterocyclylalkyl, sulfonyl, $-SO_2-(C_1-C_3$ alkyl), $-SO_3-(C_1-C_3$ alkyl), sulfonamido, carbamate, aryloxyalkyl and –C(O)NH(benzyl) groups;

R^{18} is selected from the group consisting of alkyl, alkenyl, alkynyl, hydroxyalkyl, aliphatic acyl, alkynylamino, alkoxycarbonyl, heterocycloyl, -CH=NOH, haloalkyl, alkoxyalkoxy, carboxaldehyde, carboxamide, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkylalkyl, aryl, aroyl, aryloxy, arylamino, biaryl, thioaryl, diarylamino, heterocyclyl, alkylaryl, aralkenyl, aralkyl, alkylheterocyclyl, heterocyclylalkyl, carbamate, aryloxyalkyl, hydrogen and –C(O)NH(benzyl) groups;

R^{22} is selected from the group consisting of hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, alkenoxy, alkynoxy, thioalkoxy, hydroxyalkyl, aliphatic acyl, $-CF_3$, $-CO_2H$, -SH, -CN, $-NO_2$, $-NH_2$, -OH, alkynylamino, alkoxycarbonyl, heterocycloyl, carboxy, $-N(C_1-C_3$ alkyl$)-C(O)(C_1-C_3$ alkyl), $-NHC(O)N(C_1-C_3$ alkyl$)C(O)NH(C_1-C_3$alkyl), $-NHC(O)NH(C_1-C_6$ alkyl), $-NHSO_2(C_1-C_3$ alkyl), $-NHSO_2$(aryl), alkoxyalkyl, alkylamino, alkenylamino, di(C_1-C_3)amino, $-C(O)O-(C_1-C_3)$alkyl, $-C(O)NH-(C_1-C_3)$alkyl, $-C(O)N(C_1-C_3$ alkyl$)_2$, -CH=NOH, $-PO_3H_2$,

$-OPO_3H_2$, haloalkyl, alkoxyalkoxy, carboxaldehyde, carboxamide, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkylalkyl, aryl, aroyl, aryloxy, arylamino, biaryl, thioaryl, diarylamino, heterocyclyl, alkylaryl, aralkenyl, aralkyl, alkylheterocyclyl, heterocyclylalkyl, sulfonyl, $-SO_2-(C_1-C_3$ alkyl), $-SO_3-(C_1-C_3$ alkyl), sulfonamido, carbamate, aryloxyalkyl and –C(O)NH(benzyl) groups;

c is an integer of zero to two;

d is an integer of zero to three;

e is an integer of zero to four; and

i is an integer of zero to two.

8. (Original) The composition of claim 5 wherein R^{18} is aralkyl;

R^4 is aryl;

T is $(CH_2)_b$ where b is zero;

L is $(CH_2)_n$ where n is zero; and,

B, R^6, R^7, R^9 and R^{10} are each independently hydrogen.

9. (Original) A pharmaceutical composition comprising a compound of the structure



wherein T is selected from the group consisting of C(O) and $(CH_2)_b$ wherein b is an integer of from 0 to 3;

L is selected from the group consisting of O, NR^{11}, S, and

$(CH_2)_n$ wherein n is an integer of 0 or 1;

g is an integer of from 0 to 7;

B is selected from the group consisting of hydrogen, alkyl, alkenyl,

alkynyl, hydroxyalkyl, haloalkyl, -CF_3, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkylalkyl, aryl, heterocyclyl, alkylaryl, aralkenyl, aralkyl, alkylheterocyclyl, heterocyclylalkyl and aryloxyalkyl;

R^4, R^9, R^{10} and R^{23} at each occurrence are independently selected from the group consisting of hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, alkenoxy, alkynoxy, thioalkoxy, hydroxyalkyl, aliphatic acyl, -CF_3, -CO_2H, -SH, -CN, -NO_2, -NH_2, -OH, alkynylamino, alkoxycarbonyl, heterocycloyl, carboxy, -N(C_1-C_3 alkyl)-C(O)(C_1-C_3 alkyl), -NHC(O)N(C_1-C_3 alkyl)C(O)NH(C_1-C_3alkyl), -NHC(O)NH(C_1-C_6 alkyl), -$NHSO_2$(C_1-C_3 alkyl), -$NHSO_2$(aryl), alkoxyalkyl,alkylamino, alkenylamino, di(C_1-C_3)amino, -C(O)O-(C_1-C_3)alkyl, -C(O)NH-(C_1-C_3)alkyl, -C(O)N(C_1-C_3 alkyl)$_2$, -CH=NOH, -PO_3H_2, -OPO_3H_2, haloalkyl, alkoxyalkoxy, carboxaldehyde, carboxamide, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkylalkyl, aryl, aroyl, aryloxy, arylamino, biaryl, thioaryl, diarylamino, heterocyclyl, alkylaryl, aralkenyl, aralkyl, alkylheterocyclyl, heterocyclylalkyl, sulfonyl, -SO_2-(C_1-C_3 alkyl), -SO_3-(C_1-C_3 alkyl), sulfonamido, carbamate, aryloxyalkyl and –C(O)NH(benzyl) groups;

R^6, R^7, R^{11} and R^{18} are each independently selected from the group consisting of alkyl, alkenyl, alkynyl, hydroxyalkyl, aliphatic acyl, alkynylamino, alkoxycarbonyl, heterocycloyl, -CH=NOH, haloalkyl, alkoxyalkoxy, carboxaldehyde, carboxamide, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkylalkyl, aryl, aroyl, aryloxy, arylamino, biaryl, thioaryl, diarylamino, heterocyclyl, alkylaryl, aralkenyl, aralkyl, alkylheterocyclyl, heterocyclylalkyl, carbamate, aryloxyalkyl, hydrogen and –C(O)NH(benzyl) groups;

wherein B, R^4, R^6, R^7, R^9, R^{10}, R^{11}, R^{18} and R^{23} are unsubstituted or substituted with at least one electron donating or electron withdrawing group;

wherein when L is NR^{11}, R^4 and R^{11} taken together may form a ring;

and wherein R^9 and R^{10} taken together may form a ring;

or a pharmaceutically acceptable salt thereof;

one or more other therapeutically active compounds and a pharmacologically acceptable diluent.

10. (Original) A pharmaceutical composition comprising a compound of the structure



wherein h is an integer of zero to five;

B is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, hydroxyalkyl, haloalkyl, $-CF_3$, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkylalkyl, aryl, heterocyclyl, alkylaryl, aralkenyl, aralkyl, alkylheterocyclyl, heterocyclylalkyl and aryloxyalkyl;

R^9, R^{10}, R^{24} and R^{25} are each independently selected from the group consisting of hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, alkenoxy, alkynoxy, thioalkoxy, hydroxyalkyl, aliphatic acyl, $-CF_3$, $-CO_2H$, -SH, -CN, $-NO_2$, $-NH_2$, -OH, alkynylamino, alkoxycarbonyl, heterocycloyl, carboxy, $-N(C_1\text{-}C_3$ alkyl)-$C(O)(C_1\text{-}C_3$ alkyl), $-NHC(O)N(C_1\text{-}C_3$ alkyl)$C(O)NH(C_1\text{-}C_3$alkyl), $-NHC(O)NH(C_1\text{-}C_6$ alkyl), $-NHSO_2(C_1\text{-}C_3$ alkyl), $-NHSO_2$(aryl), alkoxyalkyl, alkylamino, alkenylamino, di$(C_1\text{-}C_3)$amino, $-C(O)O\text{-}(C_1\text{-}C_3)$alkyl, $-C(O)NH\text{-}(C_1\text{-}C_3)$alkyl, $-C(O)N(C_1\text{-}C_3$ alkyl$)_2$, -CH=NOH, $-PO_3H_2$, $-OPO_3H_2$, haloalkyl, alkoxyalkoxy, carboxaldehyde, carboxamide, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkylalkyl, aryl, aroyl, aryloxy, arylamino, biaryl, thioaryl, diarylamino, heterocyclyl, alkylaryl, aralkenyl, aralkyl, alkylheterocyclyl, heterocyclylalkyl, sulfonyl, $-SO_2\text{-}(C_1\text{-}C_3$ alkyl), $-SO_3\text{-}(C_1\text{-}C_3$ alkyl), sulfonamido, carbamate, aryloxyalkyl and –C(O)NH(benzyl) groups;

R^{27}, at each occurrence, is independently selected from the group consisting of halogen, hydroxyl, alkyl, alkenyl, alkynyl, alkoxy, alkenoxy, alkynoxy, thioalkoxy, hydroxyalkyl, aliphatic acyl, $-CF_3$, $-CO_2H$, -SH, -CN, $-NO_2$, $-NH_2$, alkynylamino, alkoxycarbonyl, heterocycloyl, carboxy, $-N(C_1\text{-}C_3$ alkyl)$-C(O)(C_1\text{-}C_3$ alkyl), $-NHC(O)N(C_1\text{-}C_3$ alkyl)$C(O)NH(C_1\text{-}C_3$alkyl), $-NHC(O)NH(C_1\text{-}C_6$ alkyl), $-NHSO_2(C_1\text{-}C_3$ alkyl), $-NHSO_2$(aryl), $-N(C_1\text{-}C_3$alkyl)$SO_2(C_1\text{-}C_3$alkyl), $-N(C_1\text{-}C_3$alkyl)SO_2(aryl), alkoxyalkyl, alkylamino, alkenylamino, di($C_1\text{-}C_3$)amino, $-C(O)O\text{-}(C_1\text{-}C_3)$alkyl, $-C(O)NH\text{-}(C_1\text{-}C_3)$alkyl, $-C(O)N(C_1\text{-}C_3$ alkyl)$_2$, -CH=NOH, $-PO_3H_2$, $-OPO_3H_2$, haloalkyl, alkoxyalkoxy, carboxaldehyde, carboxamide, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkylalkyl, aryl, aroyl, aryloxy, arylamino, biaryl, thioaryl, diarylamino, heterocyclyl, alkylaryl, aralkenyl, aralkyl, alkylheterocyclyl, heterocyclylalkyl, sulfonyl, $-SO_2\text{-}(C_1\text{-}C_3$ alkyl), $-SO_3\text{-}(C_1\text{-}C_3$ alkyl), sulfonamido, carbamate, aryloxyalkyl and –C(O)NH(benzyl) groups;

R^6, R^7 and R^{18} are each independently selected from the group consisting of alkyl, alkenyl, alkynyl, hydroxyalkyl, aliphatic acyl, alkynylamino, alkoxycarbonyl, heterocycloyl, -CH=NOH, haloalkyl, alkoxyalkoxy, carboxaldehyde, carboxamide, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkylalkyl, aryl, aroyl, aryloxy, arylamino, biaryl, thioaryl, diarylamino, heterocyclyl, alkylaryl, aralkenyl, aralkyl, alkylheterocyclyl, heterocyclylalkyl, carbamate, aryloxyalkyl, hydrogen and –C(O)NH(benzyl) groups; and,

R^{26} is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, hydroxyalkyl, aliphatic acyl, $-CF_3$, alkoxycarbonyl, heterocycloyl, carboxy, $-C(O)O\text{-}(C_1\text{-}C_3)$alkyl, $-C(O)NH\text{-}(C_1\text{-}C_3)$alkyl, $-C(O)N(C_1\text{-}C_3$ alkyl)$_2$, $-PO_3H_2$, haloalkyl, carboxamide, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkylalkyl, aryl, aroyl, biaryl, heterocyclyl, alkylaryl, aralkenyl, aralkyl, alkylheterocyclyl, heterocyclylalkyl, sulfonyl, $-SO_2\text{-}(C_1\text{-}C_3$ alkyl), sulfonamido, aryloxyalkyl and –C(O)NH(benzyl) groups;

wherein B, R^6, R^7, R^9, R^{10}, R^{18}, R^{24}, R^{25}, R^{26} and R^{27} are unsubstituted or substituted with at least one electron donating or electron withdrawing group;

wherein R^{18} and R^{24} taken together may form a ring;

R^{24} and R^{25} taken together may form a ring;

R^{25} and R^{26} taken together may form a ring;

and wherein R^9 and R^{10} taken together may form a ring;

or a pharmaceutically acceptable salt thereof;

one or more other therapeutically active compounds and a pharmacologically acceptable diluent.

11. (Original) The composition of claim 10 wherein B, R^6, R^7, R^9, R^{10}, R^{24}, R^{25} and R^{26} are each independently hydrogen and R^{18} is substituted or unsubstituted aralkyl.

12. (Original) A pharmaceutical composition comprising a compound of the structure



wherein Z, at each occurrence, is independently selected from the group consisting of C(O), N, CR^{30}, $C(R^{31})(R^{32})$, NR^{33}, CH, O and S;

z is an integer of from 3 to 6;

k is an integer of from 0 to 5;

T is selected from the group consisting of C(O) and $(CH_2)_b$ wherein b is an integer of from 0 to 3;

L is selected from the group consisting of O, NR^{11}, S, and $(CH_2)_n$ wherein n is an integer of 0 or 1;

R^6, R^7, R^{11}, R^{18} and R^{33} are each independently selected from the group consisting of alkyl, alkenyl, alkynyl, hydroxyalkyl, aliphatic acyl, alkynylamino, alkoxycarbonyl, heterocycloyl, -CH=NOH, haloalkyl, alkoxyalkoxy, carboxaldehyde, carboxamide, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkylalkyl, aryl, aroyl, aryloxy, arylamino, biaryl, thioaryl, diarylamino, heterocyclyl, alkylaryl, aralkenyl, aralkyl, alkylheterocyclyl, heterocyclylalkyl, carbamate, aryloxyalkyl, hydrogen and –C(O)NH(benzyl) groups;

B is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, hydroxyalkyl, haloalkyl, $-CF_3$, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkylalkyl, aryl, heterocyclyl, alkylaryl, aralkenyl, aralkyl, alkylheterocyclyl, heterocyclylalkyl and aryloxyalkyl;

R^4, R^9, R^{10}, R^{30}, R^{31} and R^{32} at each occurrence are independently selected from the group consisting of hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, alkenoxy, alkynoxy, thioalkoxy, hydroxyalkyl, aliphatic acyl, $-CF_3$, $-CO_2H$, -SH, -OH, -CN, $-NO_2$, $-NH_2$, alkynylamino, alkoxycarbonyl, heterocycloyl, carboxy, $-N(C_1-C_3$ alkyl)$-C(O)(C_1-C_3$ alkyl), $-NHC(O)N(C_1-C_3$ alkyl$)C(O)NH(C_1-C_3$alkyl), $-NHC(O)NH(C_1-C_6$ alkyl), $-NHSO_2(C_1-C_3$ alkyl), $-NHSO_2$(aryl), alkoxyalkyl, alkylamino, alkenylamino, di(C_1-C_3)amino, $-C(O)O-(C_1-C_3)$alkyl, $-C(O)NH-(C_1-C_3)$alkyl, $-C(O)N(C_1-C_3$ alkyl$)_2$, -CH=NOH, $-PO_3H_2$, $-OPO_3H_2$, haloalkyl, alkoxyalkoxy, carboxaldehyde, carboxamide, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkylalkyl, aryl, aroyl, aryloxy, arylamino, biaryl, thioaryl, diarylamino, heterocyclyl, alkylaryl, aralkenyl, aralkyl, alkylheterocyclyl, heterocyclylalkyl, sulfonyl, $-SO_2-(C_1-C_3$ alkyl), $-SO_3-(C_1-C_3$ alkyl), sulfonamido, carbamate, aryloxyalkyl and –C(O)NH(benzyl) groups; and

R^{29}, at each occurrence, is independently selected from the group consisting of halogen, alkyl, alkenyl, alkynyl, alkoxy, alkenoxy, alkynoxy, thioalkoxy, hydroxyalkyl, aliphatic acyl, $-CF_3$, $-CO_2H$, -SH, -CN, $-NO_2$, $-NH_2$, -OH, alkynylamino, alkoxycarbonyl, heterocycloyl, carboxy, $-N(C_1-C_3$ alkyl)$-C(O)(C_1-C_3$ alkyl), $-NHC(O)N(C_1-C_3$ alkyl$)C(O)NH(C_1-C_3$alkyl), $-NHC(O)NH(C_1-C_6$ alkyl), $-NHSO_2(C_1-C_3$ alkyl), $-NHSO_2$(aryl), alkoxyalkyl, alkylamino, alkenylamino, di(C_1-C_3)amino, $-C(O)O-(C_1-C_3)$alkyl, $-C(O)NH-(C_1-C_3)$alkyl, $-C(O)N(C_1-C_3$ alkyl$)_2$, -CH=NOH, $-PO_3H_2$, $-OPO_3H_2$, haloalkyl, alkoxyalkoxy, carboxaldehyde, carboxamide, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkylalkyl, aryl, aroyl, aryloxy, arylamino, biaryl, thioaryl, diarylamino, heterocyclyl, alkylaryl, aralkenyl, aralkyl, alkylheterocyclyl, heterocyclylalkyl, sulfonyl, $-SO_2-(C_1-C_3$ alkyl), $-SO_3-(C_1-C_3$ alkyl), sulfonamido, carbamate, aryloxyalkyl and –C(O)NH(benzyl) groups;

wherein B, R^4, R^5, R^6, R^7, R^9, R^{10}, R^{11}, R^{18}, R^{29}, R^{30}, R^{31}, R^{32} and R^{33} are unsubstituted or substituted with at least one electron donating or electron withdrawing group;

wherein when L is NR^{11}, R^4 and R^{11} taken together may form a ring;

and wherein R^9 and R^{10} taken together may form a ring;

or a pharmaceutically acceptable salt thereof;

one or more other therapeutically active compounds and a pharmacologically acceptable diluent.

13. (Original) The composition of claim 12 wherein z is three or four.

14. (Original) The composition of claim 1 where the compound of structure (I) is (3S)-3-[({[1-(2-chlorobenzyl)-4-hydroxy-5-methyl-2-oxo-1,2-dihydropyridin-3-yl]amino}carbonyl)amino]-3-(4-methylphenyl)propanoic acid and pharmaceutically acceptable salts thereof.

15. (Original) The composition of claim 1 where the compound of structure (I) is (3S)-3-[({[1-(2-chlorobenzyl)-4-hydroxy-2-oxo-2,5,6,7-tetrahydro-1H-cyclopenta[b]pyridin-3-l]amino}carbonyl)amino]-3-(4-methylphenyl)propanoic acid and pharmaceutically acceptable salts thereof.

16. (Original) The composition of claim 1 where the compound of structure (I) is (3S)-3-[({[1-(2-chlorobenzyl)-4-hydroxy-5-methyl-2-oxo-1,2-dihydropyridin-3-yl]amino}carbonyl)amino]-3-[3-(diethylamino)phenyl]propanoic acid and pharmaceutically acceptable salts thereof.

17. (Original) The composition of claim 1 where the compound of structure (I) is (3S)-3-[({[1-(2-chlorobenzyl)-4-hydroxy-2-oxo-2,5,6,7-tetrahydro-1H-cyclopenta[b]pyridin-3-yl]amino}carbonyl)amino]-3-(3-isopropylphenyl)propanoic acid and pharmaceutically acceptable salts thereof.

18. (Original) The composition of claim 1 where the compound of structure (I) is (3S)-3-[({[1-(2-chlorobenzyl)-4-hydroxy-2-oxo-1,2-dihydro-1,8-napthyridin-3-yl]amino}

carbonyl)amino-3-(4-methylphenyl)propanoic acid and pharmaceutically acceptable salts thereof.

19. (Original) The composition of claim 1 where the other therapeutically active compounds are selected from the group consisting of IL-5 antagonists, CCR-3 antagonists, corticosteroids, antihistamines, Leukotrine antagonists, COX-I and COX-II inhibitors, mast cell stabilizers, anti IL-5 and anti IgE antibodies, IL-5 synthesis and release inhibitors, TNF-α inhibitors, p38 MAP kinase inhibitors, tryptase inhibitors, anticytokine/antichemokine agents, vaccines, cromolyn, selectin antagonists, PDE 4 inhibitors, β-agonists, muscarininc antagonists and immunosuppressives, CD20 antagonists and syk tyrosine kinase inhibitors.

20. (Original) A method for treating an inflammatory disease in a mammal comprising administering to said mammal a therapeutically effective amount of a composition of claim 1.

21. (Original) The method of claim 20 wherein the inflammatory disease is selected from psoriasis, asthma, atherosclerosis, multiple sclerosis, Guillan-Barr Syndrome, rheumatoid arthritis, inflammatory bowel disease and reperfusion injury.

22. (Original) A method for treating an inflammatory disease in a mammal comprising administering to said mammal a therapeutically effective amount of a combination of a compound of structure (I) in claim 1 and an effective amount of one or more other therapeutic compounds.

23. (Original) The method of claim 22 wherein the inflammatory disease is selected from psoriasis, asthma, atherosclerosis, multiple sclerosis, Guillan-Barr Syndrome, rheumatoid arthritis, inflammatory bowel disease and reperfusion injury.

24. (Original) The composition of claim 19 wherein the compound of structure (I) is selected from the group consisting of (3S)-3-[({[1-(2-chlorobenzyl)-4-hydroxy-5-methyl-2-oxo-1,2-dihydropyridin-3-yl]amino}carbonyl)amino]-3-(4-methylphenyl)propanoic acid; (3S)-3-[({[1-(2-chlorobenzyl)-4-hydroxy-2-oxo-2,5,6,7-tetrahydro-1H-cyclopenta [b]pyridin-3-l]amino}carbonyl)amino]-3-(4-methylphenyl)propanoic acid; (3S)-3-[({[1-(2-chlorobenzyl)-4-hydroxy-5-methyl-2-oxo-1,2-dihydropyridin-3-yl]amino}carbonyl)amino]-

3-[3-(diethylamino)phenyl]propanoic acid; (3S)-3-[({[1-(2-chlorobenzyl)-4-hydroxy-2-oxo-2,5,6,7-tetrahydro-1H-cyclopenta[b]pyridin-3-yl] amino}carbonyl)amino]-3-(3-isopropylphenyl)propanoic acid; and (3S)-3-[({[1-(2-chlorobenzyl)-4-hydroxy-2-oxo-1,2-dihydro-1,8-napthyridin-3-yl]amino} carbonyl) amino-3-(4-methylphenyl)propanoic acid and pharmaceutically acceptable salts thereof.

25. (Original) The method of claim 20 wherein the compound of structure (I) is selected from the group consisting of (3S)-3-[({[1-(2-chlorobenzyl)-4-hydroxy-5-methyl-2-oxo-1,2-dihydropyridin-3-yl]amino}carbonyl)amino]-3-(4-methylphenyl)propanoic acid; (3S)-3-[({[1-(2-chlorobenzyl)-4-hydroxy-2-oxo-2,5,6,7-tetrahydro-1H-cyclopenta [b]pyridin-3-l]amino}carbonyl)amino]-3-(4-methylphenyl)propanoic acid; (3S)-3-[({[1-(2-chlorobenzyl)-4-hydroxy-5-methyl-2-oxo-1,2-dihydropyridin-3-yl]amino}carbonyl)amino]-3-[3-(diethylamino)phenyl]propanoic acid; (3S)-3-[({[1-(2-chlorobenzyl)-4-hydroxy-2-oxo-2,5,6,7-tetrahydro-1H-cyclopenta[b]pyridin-3-yl] amino}carbonyl)amino]-3-(3-isopropylphenyl)propanoic acid; and (3S)-3-[({[1-(2-chlorobenzyl)-4-hydroxy-2-oxo-1,2-dihydro-1,8-napthyridin-3-yl]amino} carbonyl) amino-3-(4-methylphenyl)propanoic acid and pharmaceutically acceptable salts thereof.

26. (Original) A kit comprising in a single package, one container comprising a compound that inhibits binding of an $\alpha_4\beta_1$ integrin to its receptors as set forth in structure (I) in claim 1 in a pharmaceutically acceptable carrier and one or more separate containers comprising other therapeutic compounds in pharmaceutically acceptable carriers, with the compound that inhibits binding of $\alpha_4\beta_1$ integrin to its receptors and the other therapeutic compounds being present in amounts such that the combination is effective to treat disease states mediated by $\alpha_4\beta_1$ integrin binding.

27. (New) The method of claim 20 comprising administering a combination of a compound of claim 1 and beta interferon.

28. (New) The method of claim 27 wherein the compound of claim 1 is (3S)-3-[({[1-(2-chlorobenzyl)-4-hydroxy-2-oxo-2,5 ,6,7-tetrahydro-l H -cyclopenta[b]pyridine-3-yl] amino}carbonyl)amino]-3-(4-methylphenyl)propanoic acid or a pharmaceutically acceptable salt thereof.

29. (New) The method of claim 3 for treating multiple sclerosis comprising administering a combination of (3S)-3-[({[1-(2-chlorobenzyl)-4-hydroxy-2-oxo-2,5,6, 7-tetrahydro-1H-cyclopenta[b]pyridine-3-yl] amino}carbonyl)amino]-3-(4-methylphenyl)propanoic acid or a pharmaceutically acceptable salt thereof and beta interferon.

30. (New) The method of claim 2 comprising administering a combination of a compound of claim 1 and a corticosteroid.

31. (New) The method of claim 30 wherein the compound of claim 1 is (3S)-3-[({[1-(2-chlorobenzyl)-4-hydroxy-2-oxo-2,5,6,7-tetrahydro-IH -cyclopenta[b]pyridine-3-yl]amino}carbonyl)amino]-3-(4-methylphenyl)propanoic acid or a pharmaceutically acceptable salt thereof.

32. (New) The method of claim 30 wherein the compound of claim 1 is (3S)-3-[({[1-(2-chlorobenzyl)-4-hydroxy-2-oxo-2,5,6,7-tetrahydro-lH-cyclopenta[b]pyridine-3-yl]amino}carbonyl)amino]-3-(4-methylphenyl)propanoic acid or a pharmaceutically acceptable salt thereof and the corticosteroid is selected from the group consisting of prednisolone, fluticasone, triamcinolone, beclomethasone, mometasone, budesonide, betamethasone, dexamethasone, prednisone, flunisolide and cortisone.

33. (New) The method of claim 22 comprising administering a combination of a compound of in claim 1 and an immunosuppressant.

34. (New) The method of claim 33 wherein the compound of claim 1 is (3S)-3-[({[1-(2-chlorobenzyl)-4-hydroxy-2-oxo-2,5,6,7-tetrahydro-lH-cyclopenta[b]pyridine-3-yl] amino} -carbonyl)amino]-3-(4-methyphenyl)propanoic acid or a pharmaceutically acceptable salt thereof.

35. (New) The method of claim 22 comprising administering a combination of a compound of claim 1 and a therapeutic compound selected from the group consisting of mycophenolate mofetil, methotrexate, azathioprine and cyclophosphamide.

36. (New) The method of claim 35 wherein the compound claim 1 is (3S)-3-[({[1-(2-chlorobenzyl)-4-hydroxy-2-oxo-2,5,6,7-tetrahydro-1H-cyclopenta[b]pyridine-3-yl]amino}carbonyl)amino]-3-(4-methylphenyl)propanoic acid or a pharmaceutically acceptable salt thereof.